[1]
|
Biasi, F., Leonarduzzi, G., Oteiza, P.I. and Poli, G. (2013) Inflammatory Bowel Disease: Mechanisms, Redox Considerations, and Therapeutic Targets. Antioxidants & Redox Signaling, 19, 1711-1747. http://dx.doi.org/10.1089/ars.2012.4530
|
[2]
|
Steinmeyer, S., Lee, K., Jayaraman, A. and Alaniz, R.C. (2015) Microbiota Metabolite Regulation of Host Immune Homeostasis: A Mechanistic Missing Link. Current Allergy and Asthma Reports, 15, 524. http://dx.doi.org/10.1007/s11882-015-0524-2
|
[3]
|
Okamoto, R. and Watanabe, M. (2015) Role of Epithelial Cells in the Pathogenesis and Treatment of Inflammatory, Bowel Disease. Journal of Gastroenterology. [Epub Ahead of Print]
http://dx.doi.org/10.1007/s00535-015-1098-4
|
[4]
|
Biasi, F., Deiana, M., Guina T., Gamba, P., Leonarduzzi, G. And Poli, G. (2014) Wine Consumption and Intestinal Redox Homeostasis. Redox Biology, 18, 795-802. http://dx.doi.org/10.1016/j.redox.2014.06.008
|
[5]
|
Wan, Y.C., Li, T., Han, Y.D., Zhang, H.Y., Lin, H. and Zhang, B. (2015) Effect of Pregnane Xenobiotic Receptor Activation on Inflammatory Bowel Disease Treated with Rifaximin. Journal of Biological Regulators and Homeostatic Agents, 29, 401-410.
|
[6]
|
LeBlanc, A.M., Del Carmen, S., Chatel, J.M., Miyoshi, A., Azevedo, V., Langella, P., Bermúdez-Humarán, L.G. and LeBlanc, J.G. (2015) Current Review of Genetically Modified Lactic Acid Bacteria for the Prevention and Treatment of Colitis Using Murine Models. Gastroenterology Research and Practice, Article ID: 146972. http://dx.doi.org/10.1155/2015/146972
|
[7]
|
Moller, F.T., Andersen, V., Wohlfahrt, J. and Jess, T. (2015) Familial Risk of Inflammatory Bowel Disease: A Population-Based Cohort Study 1977-2011. The American Journal of Gastroenterology, 110, 564-571. http://dx.doi.org/10.1038/ajg.2015.50
|
[8]
|
Zhang, Y.Z. and Li, Y.Y. (2014) Inflammatory Bowel Disease: Pathogenesis. World Journal of Gastroenterology, 20, 91-99.
http://dx.doi.org/10.3748/wjg.v20.i1.91
|
[9]
|
Basso, P.J., Fonseca, M.T., Bonfá, G., et al. (2014) Association among Genetic Predisposition, Gut Microbiota, and Host Immune Response in the Etiopathogenesis of Inflammatory Bowel Disease. Brazilian Journal of Medical and Biological Research, 47, 727-737. http://dx.doi.org/10.1590/1414-431X20143932
|
[10]
|
Tabbaa, M., Golubic, M., Roizen, M.F. and Bernstein, A.M. (2013) Docosahexaenoic Acid, Inflammation, and Bacterial Dysbiosis in Relation to Periodontal Disease, Inflammatory Bowel Disease, and the Metabolic Syndrome. Nutrients, 5, 3299-3310.
http://dx.doi.org/10.3390/nu5083299
|
[11]
|
Brandse, J.F., Vos, L.M., Jansen, J., Schakel, T., Ponsioen, C.I., van den Brink, G.R., D’Haens, G.R. and Löwenberg, M. (2015) Serum Concentration of Anti-TNF Antibodies, Adverse Effects and Quality of Life in Patients with Inflammatory Bowel Disease in Remission on Maintenance Treatment. Journal of Crohn’s and Colitis. [Epub ahead of print]
|
[12]
|
Cheifetz, A.S. (2013) Management of Active Crohn Disease. JAMA, 309, 2150-2158. http://dx.doi.org/10.1001/jama.2013.4466
|
[13]
|
Molodecky, N.A., Soon, I.S., Rabi, D.M., Ghali, W.A., Ferris, M., Chernoff, G., Benchimol, E.I., Panaccione, R., Ghosh, S., Barkema, H.W. and Kaplan, G.G. (2012) Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases with Time, Based on Systematic Review. Gastroenterology, 142, 46-54. http://dx.doi.org/10.1053/j.gastro.2011.10.001
|
[14]
|
Nadorp, B. and Soreq, H. (2015) Gut Feeling: MicroRNA Discriminators of the Intestinal TLR9-Cholinergic Links. International Immunopharmacology. [Epub ahead of print]
|
[15]
|
Serhan, C.N. and Savill, J. (2005) Resolution of Inflammation: The Beginning Programs the End. Nature Immunology, 6, 1191-1197.
http://dx.doi.org/10.1038/ni1276
|
[16]
|
De Cruz, P., Prideaux, L., Wagner, J., Ng, S.C., McSweeney, C., Kirkwood, C., et al. (2012) Characterization of the Gastrointestinal Microbiota in Health and Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 18, 372-390. http://dx.doi.org/10.1002/ibd.21751
|
[17]
|
Medzhitov, R. (2010) Inflammation 2010: New Adventures of an Old Flame. Cell, 140, 771-776. http://dx.doi.org/10.1016/j.cell.2010.03.006
|
[18]
|
Nasef, N.A., Mehta, S., Powell, P., Marlow, G., Wileman, T. and Ferguson, L.R. (2015) Extracts of Feijoa Inhibit Toll-Like Receptor 2 Signaling and Activate Autophagy Implicating a Role in Dietary Control of IBD. PLoS ONE, 10, e0130910. http://dx.doi.org/10.1371/journal.pone.0130910
|
[19]
|
Silverberg, M.S., Satsangi, J., Ahmad, T., Arnott, I.D., Bernstein, C.N., Brant, S.R., Caprilli, R., Colombel, J.F., Gasche, C. and Geboes, K. (2005) Toward an Integrated Clinical, Molecular and Serological Classification of Inflammatory Bowel Disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Canadian Journal of Gastroenterology, 19, 5A-36A.
|
[20]
|
Shores, D.R., Binion, D.G., Freeman, B.A. and Baker, P.R. (2011) New Insights into the Role of Fatty Acids in the Pathogenesis and Resolution of Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 17, 2192-2204. http://dx.doi.org/10.1002/ibd.21560
|
[21]
|
Pavlov, V.A. and Tracey, K.J. (2012) Thevagus Nerve and the Inflammatory Reflex-Linking Immunity and Metabolism. Nature Reviews Endocrinology, 8, 743-754. http://dx.doi.org/10.1038/nrendo.2012.189
|
[22]
|
Krieg, A.M. and Vollmer, J. (2007) Toll-Like Receptors 7, 8, and 9: Linking Innate Immunity to Autoimmunity. Immunological Reviews, 220, 251-269. http://dx.doi.org/10.1111/j.1600-065x.2007.00572.x
|
[23]
|
Bonizzi, G. and Karin, M. (2004) The Two NF-κB Activation Pathways and Their Role in Innate and Adaptive Immunity. Trends in Immunology, 25, 280-288. http://dx.doi.org/10.1016/j.it.2004.03.008
|
[24]
|
Paraskevi, A., Theodoropoulos, G., Papaconstantinou, I., Mantzaris, G., Nikiteas, N. and Gazouli, M. (2012) Circulating MicroRNA in Inflammatory Bowel Disease. Journal of Crohn’s and Colitis, 6, 900-904. http://dx.doi.org/10.1016/j.crohns.2012.02.006
|
[25]
|
Tas, S.W., Vervoordeldonk, M.J., Hajji, N., Schuitemaker, J.H., van der Sluijs, K.F. and May, M.J. (2007) Noncanonical NF-κB Signaling in Dendritic Cells Is Required for Indoleamine 2,3-Dioxygenase (IDO) Induction and Immune Regulation. Blood, 110, 1540-1549. http://dx.doi.org/10.1182/blood-2006-11-056010
|
[26]
|
Sailaja, B.S., Cohen-Carmon, D., Zimmerman, G., Soreq, H. and Meshorer, E. (2012) Stress-Induced Epigenetic Transcriptional Memory of Acetylcholinesterase by HDAC4. Proceedings of the National Academy of Sciences of the United States of America, 109, E3687-E3695. http://dx.doi.org/10.1073/pnas.1209990110
|
[27]
|
Zimmerman, G., Shaltiel, G., Barbash, B., Cohen, J., Gasho, C.J. and Shenhar-Tsarfaty, S. (2012) Post-Traumatic Anxiety Associates with Failure of the Innate Immune Receptor TLR9 to Evade the Pro-Inflammatory NFκB Pathway. Translational Psychiatry, 2, e78. http://dx.doi.org/10.1038/tp.2012.4
|
[28]
|
Netjes, J.E. and Rijken, M. (2013) Labor Participation among Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 19, 81-91. http://dx.doi.org/10.1002/ibd.22921
|
[29]
|
Devlen, J., Beusterien, K., Yen, L., Ahmed, A., Cheifetz, A.S. and Moss, A.C. (2014) Barriers to Mesalamine Adherence in Patients with Inflammatory Bowel Disease: A Qualitative Analysis. J Manag Care Spec Pharm, 20, 309-314.
|
[30]
|
Bielefeldtand, K., Davis, B. and Binion, D.G. (2009) Pain and Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 15, 778-788.
http://dx.doi.org/10.1002/ibd.20848
|
[31]
|
Aghazadeh, R., Zali, M.R., Bahari, A., Amin, K., Ghahghaie, F. and Firouzi, F. (2005) Inflammatory Bowel Disease in Iran: A Review of 457 Cases. Journal of Gastroenterology and Hepatology, 20, 1691-1695. http://dx.doi.org/10.1111/j.1440-1746.2005.03905.x
|
[32]
|
Lix, L.M., Graff, L.A., Walker, J.R., Clara, I., Rawsthorne, P., Rogala, L., Miller, N., Ediger, J., Pretorius, T. and Bernstein, C. (2008) Longitudinal Study of Quality of Life and Psychological Functioning for Active, Fluctuating, and Inactive Disease Patterns in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 14, 1575-1584. http://dx.doi.org/10.1002/ibd.20511
|
[33]
|
Kappelman, M.D., Rifas-Shiman, S.L., Kleinman, K., Ollendorf, D., Bousvaros, A., Grand, R.J. and Finkelstein, J.A. (2007) The Prevalence and Geographic Distribution of Crohn’s Disease and Ulcerative Colitis in the United States. Clinical Gastroenterology and Hepatology, 5, 1424-1429. http://dx.doi.org/10.1016/j.cgh.2007.07.012
|
[34]
|
Burisch, J., Jess, T., Martinato, M. and Lakatos, P. (2013) The Burden of Inflammatory Bowel Disease in Europe, on Behalf of ECCO-EpiCom. Journal of Crohn’s and Colitis, 7, 322-337.
http://dx.doi.org/10.1016/j.crohns.2013.01.010
|
[35]
|
Matricon, J. (2010) Immunopathogenèse des maladies inflammatoireschroniques de l’intestin. M/S n° 4, vol. 26.
|
[36]
|
Lorén, V., Cabré, E., Ojanguren, I., Domènech, E., Pedrosa, E., García-Jaraquemada, A., et al. (2015) Interleukin-10 Enhances the Intestinal Epithelial Barrier in the Presence of Corticosteroids through p38 MAPK Activity in Caco-2 Monolayers: A Possible Mechanism for Steroid Responsiveness in Ulcerative Colitis. PLoS ONE, 10, e0130921. http://dx.doi.org/10.1371/journal.pone.0130921
|
[37]
|
Longui, C.A. (2007) Glucocorticoid Therapy: Minimizing Side Effects. Jornal de Pediatria, 83, S163-S171. http://dx.doi.org/10.2223/jped.1713
|
[38]
|
Brunton, L.L., Chabner, B.A. and Knollmann, B.C. (2012) Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 12th Edition, AMGH Editora, Porto Alegre.
|
[39]
|
Moss, A.C. and Peppercorn, M.A. (2007) The Risks and the Benefits of Mesalazine as a Treatment for Ulcerative Colitis. Expert Opinion on Drug Safety, 6, 99-107. http://dx.doi.org/10.1517/14740338.6.2.99
|
[40]
|
Feagan, B.G., Chande, N. and MacDonald, J.K. (2009) Are There Any Differences in the Efficacy and Safety of Different Formulations of Oral 5-ASA Used for Induction and Maintenance of Remission in Ulcerative Colitis? Evidence from Cochrane Reviews. Inflammatory Bowel Diseases, 19, 2031-2040.
|
[41]
|
Kawashima, K., Ishihara, S., Yuki, T., Onishi, K., Kushiyama, Y., Fujishiro, H., et al. (2014) Therapeutic Efficacy of pH-Dependent Release Formulation of Mesalazine on Active Ulcerative Colitis Resistant to Time-Dependent Release Formulation: Analysis of Fecal Calprotectin Concentration. BioMed Research International, 2014, Article ID: 342751. http://dx.doi.org/10.1155/2014/342751
|
[42]
|
Riley, S.A., Tavares, I.A., Bennett, A. and Mani, V. (1988) Delayed-Release Mesalazine (5-Aminosalicylic Acid): Coat Dissolution and Excretion in Ileostomy Subjects. British Journal of Clinical Pharmacology, 26, 173-177. http://dx.doi.org/10.1111/j.1365-2125.1988.tb03383.x
|
[43]
|
Fernandez-Becker, N.Q. and Moss, A.C. (2008) Improving Delivery of Aminosalicylates in Ulcerative Colitis: Effect on Patient Outcomes. Drugs, 68, 1089-1103. http://dx.doi.org/10.2165/00003495-200868080-00006
|
[44]
|
D’Incà, R., Paccagnella, M., Cardin, R., Pathak, S., Baldo, V., Giron, M.C. and Sturniolo, G.C. (2013) 5-ASA Colonic Mucosal Concentrations Resulting from Different Pharmaceutical Formulations in Ulcerative Colitis. World Journal of Gastroenterology, 19, 5665-5670. http://dx.doi.org/10.3748/wjg.v19.i34.5665
|
[45]
|
Thomas, C.W., Myhre, G.M., Tschumper, R., Sreekumar, R., Jelinek, D., McKean, D.J., Lipsky, J.J., Sandborn, W.J. and Egan, L.J. (2005) Selective Inhibition of Inflammatory Gene Expression in Activated T Lymphocytes: A Mechanism of Immune Suppression by Thiopurines. Journal of Pharmacology and Experimental Therapeutics, 312, 537-545. http://dx.doi.org/10.1124/jpet.104.074815
|
[46]
|
Engelhardt, B. and Briskin, M.J. (2005) Therapeutic Targeting of α4-Integrins in Chronic Inflammatory Diseases: Tipping the Scales of Risk towards Benefit? European Journal of Immunology, 35, 2268-2273. http://dx.doi.org/10.1002/eji.200535195
|
[47]
|
Swaminath, A., Taunk, R. and Lawlor, G. (2014) Use of Methotrexate in Inflammatory Bowel Disease in 2014: A User’s Guide. World Journal of Gastrointestinal Pharmacology and Therapeutics, 5, 113-121. http://dx.doi.org/10.4292/wjgpt.v5.i3.113
|
[48]
|
Wahed, M., Louis-Auguste, J.R., Baxter, L.M., Limdi, J.K., McCartney, S.A., Lindsay, J.O. and Bloom, S.L. (2009) Efficacy of Methotrexate in Crohn’s Disease and Ulcerative Colitis Patients Unresponsive or Intolerant to Azathioprine/Mercaptopurine. Alimentary Pharmacology & Therapeutics, 30, 614-620. http://dx.doi.org/10.1111/j.1365-2036.2009.04073.x
|
[49]
|
Absah, I. and Faubion, W.A. (2012) Concomitant Therapy with Methotrexate and Anti-TNF-α in Pediatric Patients with Refractory Crohn’s Colitis: A Case Series. Inflammatory Bowel Diseases, 18, 1488-1492. http://dx.doi.org/10.1002/ibd.21885
|
[50]
|
Ko, J.K. and Auyeung, K.K. (2014) Inflammatory Bowel Disease: Etiology, Pathogenesis and Current Therapy. Current Pharmaceutical Design, 20, 1082-1096. http://dx.doi.org/10.2174/13816128113199990416
|
[51]
|
Löwenberg, M. and D’Haens, G. (2015) Next-Generation Therapeutics for IBD. Current Gastroenterology Reports, 17, 21.
http://dx.doi.org/10.1007/s11894-015-0444-2
|
[52]
|
Xu, Z., Davis, H.M. and Zhou, H. (2015) Clinical Impact of Concomitant Immunomodulators on Biologic Therapy: Pharmacokinetics, Immunogenicity, Efficacy and Safety. Journal of Clinical Pharma, 55, S60-S74. http://dx.doi.org/10.1002/jcph.380
|
[53]
|
Actis, G.C., Pellicano, R. and Rosina, F. (2015) Inflammatory Bowel Disease: Traditional Knowledge Holds the Seeds for the Future. World Journal of Gastrointestinal Pharmacology and Therapeutics, 6, 10-16. http://dx.doi.org/10.4292/wjgpt.v6.i2.10
|
[54]
|
Gungor, O.E., Kirzioglu, Z. and Kivanc, M. (2015) Probiotics: Can They Be Used to Improve Oral Health? Beneficial Microbes. [Epub ahead of print]
|
[55]
|
Fujimori, S. (2015) What Are the Effects of Proton Pump Inhibitors on the Small Intestine? World Journal of Gastroenterology, 21, 6817-6819.
|
[56]
|
Petrof, E.O. and Khoruts, A. (2014) From Stool Transplants to Next-Generation Microbiota Therapeutics. Gastroenterology, 146, 1573-1582. http://dx.doi.org/10.1053/j.gastro.2014.01.004
|
[57]
|
Khoruts, A., Dicksved, J., Jansson, J.K. and Sadowsky, M.J. (2010) Changes in the Composition of the Human Fecal Microbiome after Bacteriotherapy for Recurrent Clostridium Difficile-Associated Diarrhea. Journal of Clinical Gastroenterology, 44, 354-360.
|
[58]
|
Ng, S.C., Hart, A.L., Kamm, M.A., Stagg, A.J. and Knight, S.C. (2009) Mechanisms of Action of Probiotics: Recent Advances. Inflammatory Bowel Diseases, 15, 300-310. http://dx.doi.org/10.1002/ibd.20602
|
[59]
|
Caballero-Franco, C.K., Simone, K.C.D. and Chadee, K. (2007) The VSL#3 Probiotic Formula Induces Mucin Gene Expression and Secretion in Colonic Epithelial Cells. The American Journal of Physiology—Gastrointestinal and Liver Physiology, 292, G315-G322. http://dx.doi.org/10.1152/ajpgi.00265.2006
|
[60]
|
Kruidenier, L. and Verspaget, H.W. (2002) Review Article: Oxidative Stress as a Pathogenic Factor in Inflammatory Bowel Disease—Radicals or Ridiculous? Alimentary Pharmacology and Therapeutics, 16, 1997-2015. http://dx.doi.org/10.1046/j.1365-2036.2002.01378.x
|
[61]
|
Grompone, G.P. and Llopis, S.M. (2012) Anti-Inflammatory Lactobacillus rhamnosus CNCM I-3690 Strain Protects against Oxidative Stress and Increases Lifespan in Caenorhabditis elegans. PLoS ONE, 7, e52493. http://dx.doi.org/10.1371/journal.pone.0052493
|
[62]
|
Zagato, E., Mileti, E. and Massimiliano, L. (2014) Lactobacillus Paracasei CBA L74 Metabolic Products and Fermented Milk for Infant Formula Have Anti-Inflammatory Activity on Dendritic Cells in Vitro and Protective Effects against Colitis and an Enteric Pathogen in Vivo. PLoS ONE, 9, e87615. http://dx.doi.org/10.1371/journal.pone.0087615
|
[63]
|
Kaci, G., Goudercourt, D. and Dennin, V. (2014) Anti-Inflammatory Properties of Streptococcus salivarius, a Commensal Bacterium of the Oral Cavity and Digestive Tract. Applied and Environmental Microbiology, 80, 928-934. http://dx.doi.org/10.1128/AEM.03133-13
|
[64]
|
Duary, R.K., Bhausaheb, M.A., Batish, V.K. and Grover, S. (2012) Anti-Inflammatory and Immunomodulatory Efficacy of Indigenous Probiotic Lactobacillus plantarum Lp91 in Colitis Mouse Model. Molecular Biology Reports, 39, 4765-4775.
http://dx.doi.org/10.1007/s11033-011-1269-1
|
[65]
|
Fernandez, E.M., Valenti, V. and Rocke, C. (2011) Anti-Inflammatory Capacity of Selected Lactobacilli in Experimental Colitis Is Driven by NOD2-Mediated Recognition of a Specific Peptidoglycan-Derived Muropeptide. Gut, 60, 1050-1059. http://dx.doi.org/10.1136/gut.2010.232918
|
[66]
|
Chaves, S., Perdigon, G. and LeBlanc, A.M. (2011) Yoghurt Consumption Regulates the Immune Cells Implicated in Acute Intestinal Inflammation and Prevents the Recurrence of the Inflammatory Process in a Mouse Model. Journal of Food Protection, 74, 801-811.
http://dx.doi.org/10.4315/0362-028X.JFP-10-375
|
[67]
|
Rea, M.C., Clayton, E. and O’Connor, P.M. (2007) Antimicrobial Activity of Lacticin 3147 against Clinical Clostridium Difficile Strains. Journal of Medical Microbiology, 56, 940-946. http://dx.doi.org/10.1099/jmm.0.47085-0
|
[68]
|
O’Mahony, L., Feeney, M. and O’Halloran, S. (2001) Probiotic Impact on Microbial Flora, Inflammation and Tumour Development in IL-10 Knockout Mice. Alimentary Pharmacology and Therapeutics, 15, 1219-1225. http://dx.doi.org/10.1046/j.1365-2036.2001.01027.x
|
[69]
|
Hill, C., Guarner, F. and Reid, G. (2014) Expert Consensus Document: The International Scientific Association for Probiotics and Prebiotics Consensus Statement on the Scope and Appropriate Use of the Term Probiotic. Nature Reviews Gastroenterology & Hepatology, 11, 506-514. http://dx.doi.org/10.1038/nrgastro.2014.66
|
[70]
|
Yoshimatsu, Y., Yamada, A., Furukawa, R., Sono, K., Osamura, A., Nakamura, K., Aoki, H., Tsuda, Y., Hosoe, N., Takada, N. and Suzuki, Y. (2015) Effectiveness of Probiotic Therapy for the Prevention of Relapse in Patients with Inactive Ulcerative Colitis. World Journal of Gastroenterology, 21, 5985-5994.
|
[71]
|
Cruchet, S., Furnes, R., Maruy, A., Hebel, E., Palacios, J., Medina, F., et al. (2015) The Use of Probiotics in Pediatric Gastroenterology: A Review of the Literature and Recommendations by Latin-American Experts. Paediatric Drugs, 17, 199-216.
http://dx.doi.org/10.1007/s40272-015-0124-6
|
[72]
|
Ghouri, Y.A., Richards, D.M., Rahimi, E.F., Krill, J.T., Jelinek, K.A. and DuPont, A.W. (2014) Systematic Review of Randomized Controlled Trials of Probiotics, Prebiotics, and Synbiotics in Inflammatory Bowel Disease. Clinical and Experimental Gastroenterology, 7, 473-487.
|
[73]
|
Sartor, R.B. (2008) Microbial Influences in Inflammatory Bowel Diseases. Gastroenterology, 134, 577-594. http://dx.doi.org/10.1053/j.gastro.2007.11.059
|
[74]
|
Eckburg, P.B., Bik, E.M., Bernstein, C.N., Purdom, E., Dethlefsen, L., Sargent, M., et al. (2005) Diversity of the Human Intestinal Microbial Flora. Science, 308, 1635-1638.
http://dx.doi.org/10.1126/science.1110591
|
[75]
|
Asakura, H., Suzuki, K. and Honma, T. (2007) Recent Advances in Basic and Clinical Aspects of Inflammatory Bowel Disease: Which Steps in the Mucosal Inflammation Should We Block for the Treatment of Inflammatory Bowel Disease? World Journal of Gastroenterology, 13, 2145-2149. http://dx.doi.org/10.3748/wjg.v13.i15.2145
|
[76]
|
Steer, T., Carpenter, H., Tuohy, K. and Gibson, G.R. (2000) Perspectives on the Role of the Human Gut Microbiota and Its Modulation by Pro- and Prebiotics. Nutrition Research Reviews, 13, 229-254. http://dx.doi.org/10.1079/095442200108729089
|
[77]
|
Othman, M., Agüero, R. and Lin, H.C. (2008) Alterations in Intestinal Microbial Flora and Human Disease. Current Opinion in Gastroenterology, 24, 11-16. http://dx.doi.org/10.1097/mog.0b013e3282f2b0d7
|
[78]
|
Mai, V. and Draganov, P.V. (2009) Recent Advances and Remaining Gaps in Our Knowledge of Associations between Gut Microbiota and Human Health. World Journal of Gastroenterology, 15, 81-85. http://dx.doi.org/10.3748/wjg.15.81
|
[79]
|
Shadnoush, M., Hosseini, R.S., Khalilnezhad, A., Navai, L., Goudarzi, H. and Vaezjalali, M. (2015) Effects of Probiotics on Gut Microbiota in Patients with Inflammatory Bowel Disease: A Double-Blind, Placebo-Controlled Clinical Trial. The Korean Journal of Gastroenterology, 65, 215-221.
http://dx.doi.org/10.4166/kjg.2015.65.4.215
|
[80]
|
Gibson, G.R. and Roberfroid, M.B. (1995) Dietary Modulation of the Human Colonic Microbiota: Introducing the Concept of Prebiotics. Journal of Nutrition, 125, 1401-1412.
|
[81]
|
O’Mahony, L., Feeney, M., O’Halloran, S., Murphy, L., Kiely, B., Fitzgibbon, J., et al. (2001) Probiotic Impact on Microbial Flora, Inflammation and Tumour Development in IL-10 Knockout Mice. Alimentary Pharmacology and Therapeutics, 15, 1219-1225. http://dx.doi.org/10.1046/j.1365-2036.2001.01027.x
|
[82]
|
Guarino, A., Vecchio, A.L. and Canani, R.B. (2009) Probiotics as Prevention and Treatment for Diarrhea. Current Opinion in Gastroenterology, 25, 18-23. http://dx.doi.org/10.1097/mog.0b013e32831b4455
|
[83]
|
Indriyani, S. (2012) Effects of Live versus Heat-Killed Probiotics on Acute Diarrhea in Young Children. Paediatrica Indonesiana, 52, 249-254. http://dx.doi.org/10.14238/pi52.5.2012.01
|
[84]
|
Lutgendorff, F., Akkermans, L. and Soderholm, J. (2008) The Role of Microbiota and Probiotics in Stress-Induced Gastro-Intestinal Damage. Current Molecular Medicine, 282-298.
http://dx.doi.org/10.2174/156652408784533779
|
[85]
|
Gerritsen, J., Smidt, H., Rijkers, G.T. and de Vos, W.M. (2011) Intestinal Microbiota in Human Health and Disease: The Impact of Probiotics. Genes & Nutrition, 6, 209-240. http://dx.doi.org/10.1007/s12263-011-0229-7
|
[86]
|
Scaldaferri, F., Gerardi, V., Lopetuso, L.R., Del Zompo, F., Mangiola, F., Boskoski, I., et al. (2013) Gut Microbial Flora, Prebiotics, and Probiotics in IBD: Their Current Usage and Utility. BioMed Research International, 2013, Article ID: 435268. http://dx.doi.org/10.1155/2013/435268
|
[87]
|
Bergstrand, L.O., Gustafsson, B.E., Holmstrom, B. and Norin, K.E. (1981) The Physiological Activity of Human Ileal Flora in Patients with Crohn’s Disease and Ulcerative Colitis Evaluated by Determination of Germfree Animal Characteristics. Actachirscand, 147, 707-709.
|
[88]
|
Van der Merve, J.P. and Mol, G.J.J. (1982) Levels of Trypsin and Alpha-Chymotrypsin in Feces from Patients with Crohn’s Disease. Digestion, 24, 1-4. http://dx.doi.org/10.1159/000198767
|
[89]
|
Midtvedt, T., Zabarovsky, E., Norin, E., Bark, J., Gizatullin, R., Kashuba, V., et al. (2013) Increase of Faecal Tryptic Activity Relates to Changes in the Intestinal Microbiome: Analysis of Crohn’s Disease with a Multidisciplinary Platform. PLoS ONE, 8, e66074. http://dx.doi.org/10.1371/journal.pone.0066074
|